(Q36548708)

14 August 2017

1 reference

title

Hospital-acquired pneumonia in the 21st century: a review of existing treatment options and their impact on patient care (English)

1 reference

hospital-acquired pneumonia

14 August 2017

main subject

1 reference

Despoina Koulenti

1

0 references

Jordi Rello

object named as

Jordi Rello

series ordinal

2

0 references

language of work or name

English

0 references

publication date

1 August 2006

1 reference

Expert Opinion on Pharmacotherapy

14 August 2017

published in

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

12

1 reference

14 August 2017

page(s)

1555-1569

1 reference

Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

The effect of late-onset ventilator-associated pneumonia in determining patient mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Bench-to-bedside review: Therapeutic options and issues in the management of ventilator-associated bacterial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Microbiologic diagnosis of ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: influence of disease severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Appropriateness and delay to initiate therapy in ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Risk factors for infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Ventilator-associated pneumonia in a multi-hospital system: differences in microbiology by location

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Diagnostic testing for ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Role of bronchoalveolar lavage in mechanically ventilated patients with suspected pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Effects of cigarette smoking on lung function in adolescent boys and girls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Influence of Pharmacokinetic and Pharmacodynamic Principles on Antibiotic Selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Implications of endotracheal tube biofilm for ventilator-associated pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

The diagnosis of ventilator-associated pneumonia: a comparison of histologic, microbiologic, and clinical criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Clinical resolution in patients with suspicion of ventilator-associated pneumonia: a cohort study comparing patients with and without acute respiratory distress syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

A comparative analysis of patients with early-onset vs late-onset nosocomial pneumonia in the ICU setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Advances in the management of pneumonia in the intensive care unit: review of current thinking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

BAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Prevention of gram negative nosocomial bronchopneumonia by intratracheal colistin in critically ill patients. Histologic and bacteriologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Aerosolized ceftazidime for prevention of ventilator-associated pneumonia and drug effects on the proinflammatory response in critically ill trauma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Etiology of ventilator-associated pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Comparison of continuous with discontinuous intravenous infusion of vancomycin in severe MRSA infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Antibiotics for gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Methicillin-Resistant S. aureus Ventilator-Associated Pneumonia: Strategies to Prevent and Treat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Vancomycin for Staphylococcus aureus therapy of respiratory tract infections: the end of an era?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Intrapulmonary pharmacokinetics of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Linezolid resistance in a clinical isolate of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Trends in antimicrobial susceptibility in UK centres: the MYSTIC Programme (1997-2002).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Plasmid-mediated, carbapenem-hydrolysing beta-lactamase, KPC-2, in Klebsiella pneumoniae isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

The need for new therapeutic agents: what is the pipeline?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Epidemiology and Outcomes of Ventilator-Associated Pneumonia in a Large US Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Survival in patients with nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

De-escalation therapy in ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

Secretion of the Toxin ExoU Is a Marker for Highly VirulentPseudomonas aeruginosaIsolates Obtained from Patients with Hospital‐Acquired Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1555

10.1517/14656566.7.12.1555

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference